Highlights
A collection of news and information related to AstraZeneca Plc published by this site and its partners.
Displaying items 1-12 of 74
» View wsbtradio.com items only
1
2
3
4
5
6
7
•
Next >
-
Bernanke spurs stock volatility, dollar gains
ReutersNEW YORK (Reuters) - Stocks, bonds and currencies took a wild ride on Wednesday after Federal Reserve Chairman Ben Bernanke said the U.S. central bank's massive bond-buying program would remain in place for now, even as the Fed considers cutting back...Tags: Annapolis, Lebanon, Stock Activities, Robin Williams, Finance
-
Immune system cancer drugs tipped to be a $35 bln market
Reuters* Potential sales of $35 bln a year over next 10 years - Citigroup * Immunotherapy may be used in up to 60 percent of cancers * Bristol-Myers Squibb and Roche both upgraded to "buy" By Ben Hirschler LONDON, May 22 (Reuters) - A new wave of medicines...Tags: Oncology, Food and Drug Administration, GlaxoSmithKline PLC, Amgen Inc., Science and Technology
-
Immune system cancer drugs tipped to be a $35 billion market
ReutersLONDON (Reuters) - A new wave of medicines that tap the power of the immune system to fight cancer could become the biggest drug class in history, with potential sales of $35 billion a year. That bullish sales forecast by analysts at U.S. bank...Tags: Oncology, GlaxoSmithKline PLC, Food and Drug Administration, Science and Technology, Amgen Inc.
-
Inmunoterapia contra el cáncer podría ser un mercado de 35.000 mln dlrs anuales
ReutersPor Ben Hirschler LONDRES, 22 may (Reuters) - Una nueva ola de medicinas que emplea el poder del sistema inmunológico para luchar contra el cáncer podría convertirse en el mayor grupo de medicamentos de la historia, con ventas potenciales de 35.000...Tags: Citigroup Incorporated, Merck & Company Incorporated, GlaxoSmithKline PLC, Amgen Inc., Roche Holding AG
-
AstraZeneca closes in on site for new home in Cambridge
Reuters* Drugmaker eyes Cambridge Biomedical Campus - sources * Relocation centrepiece of new CEO's restructuring plan * New research centre and corporate HQ to cost some $500 mln By Ben Hirschler and Tom Bill LONDON, May 20 (Reuters) - AstraZeneca is...Tags: Science and Technology, Cambridge (England), Research, MedImmune Inc., University of Cambridge
-
Mexicana Genomma Lab distribuirá marca de antiácidos Losec
ReutersMONTERREY, 20 mayo (Reuters) - La farmacéutica mexicana Genomma Lab dijo el lunes que firmó un contrato de licencia para el uso de la marca de medicamentos de libre venta Losec, que le permitirá distribuir el popular antiácido por 99 años. Genomma... -
AstraZeneca accelerates cancer drug testing
ReutersLONDON (Reuters) - AstraZeneca has enrolled the first patient into a final-stage clinical trial of a new drug for a rare type of leukemia as the group's new CEO delivers on a promise to accelerate its oncology programs. Britain's second-biggest drugmaker...Tags: Oncology, Trials, Science and Technology, Drugs and Medicines, Lung Cancer
-
Cubist bid almost $1 bln for Optimer before sale process-sources
ReutersBy Jessica Toonkel NEW YORK, May 15 (Reuters) - Before Optimer Pharmaceuticals Inc even put itself up for sale earlier this year, Cubist Pharmaceuticals Inc offered to buy the antibiotic maker for $20 per share, or nearly $1 billion, two people...Tags: Diarrhea, Japan, Thomson Corporation, Cubist Pharmaceuticals Incorporated
-
Cubist bid for Optimer before sale process began: sources
ReutersNEW YORK (Reuters) - Before Optimer Pharmaceuticals Inc even put itself up for sale earlier this year, Cubist Pharmaceuticals Inc offered to buy the antibiotic maker for $20 per share, or nearly $1 billion, two people familiar with the matter told Reuters...Tags: Diarrhea, Japan, Thomson Corporation, Cubist Pharmaceuticals Incorporated
-
A taste for defensives sours prospects for European stocks
Reuters* Defensive stocks unusually leading Europe stock rally * Healthcare price/earnings ratios at five-year highs * Fund managers still favour defensives -BofA ML survey By Tricia Wright LONDON, May 14 (Reuters) - Defensive stocks such as healthcare...Tags: Earnings, Pharmaceuticals, Finance, Economy, Business and Finance, Thomson Corporation
-
RPT-ANALYSIS-Drugmakers face more scrutiny of discordant U.S. prices
Reuters(Repeats to widen readership) By Deena Beasley LOS ANGELES, May 10 (Reuters) - The world's biggest drug makers have for years enjoyed rich premiums for their medicines in the U.S. market. Those days may be coming to an end. Companies like Pfizer Inc...Tags: Ernst & Young, Science and Technology, Culture, Arts and Culture, Career and Workplace
-
U.S. spending on medicines fell for first time in 2012
Reuters(Reuters) - Patent expirations on big-name drugs such as Lipitor and Plavix has resulted in modestly less spending on medicines in the United States for the first time in at least 55 years, according to a report released on Thursday. Overall U.S....Tags: Patents, Copyrights and Trademarks, Health Insurance Cost, Flu, Pfizer Inc., Bristol Myers Squibb Company
May 22, 2013
|Story| Reuters
May 22, 2013
|Story| Reuters
May 22, 2013
|Story| Reuters
May 22, 2013
|Story| Reuters
May 20, 2013
|Story| Reuters
May 20, 2013
|Story| Reuters
May 16, 2013
|Story| Reuters
May 15, 2013
|Story| Reuters
May 15, 2013
|Story| Reuters
May 14, 2013
|Story| Reuters
May 10, 2013
|Story| Reuters
May 8, 2013
|Story| Reuters
Original site for AstraZeneca Plc topic gallery.
